Abstract

Type 2 diabetes is a common and chronic condition with a rapidly growing prevalence. Cardiovascular events are the main reason for death in type 2 diabetes, hence prevention and treatments of cardiovascular disease should be the main point of concern in diabetes. Glucagon-like peptide-1 receptor agonists not only reduce the risks contributing to cardiovascular events such as glycaemia, body weight, dyslipidaemia, and hypertension but also improve the endothelial function, ischemia, and heart failure. Recent clinical trials on cardiovascular events have been performed with GLP-1 agonists. In these trials, liraglutide and semaglutide have revealed to be superior in cardiovascular outcomes. The mechanisms of showing cardiovascular benefits by liraglutide and semaglutide are still not known but it is recommended for these benefits to use these therapeutic regimes routinely in the clinical practice [1].

Keywords: Type 2 Diabetes; Pharmacology; GLP-1

References

1. Isabel del Olmo-Garcia M., et al. “GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes”. Journal of Diabetes Research 2018 (2018): 4020492.
2. Hinnen D. “Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes”. Diabetes Spectrum3 (2017): 202-210.
3. Andrikou E., et al. “GLP-1 receptor agonists and cardiovascular outcome trials: An update”. Hellenic Journal of Cardiology6 (2019): 347-351.
4. “Round-up of the GLP-1 receptor agonist CV outcome trials”. 2017, Medicine Matters, Diabetes (2017).
5. Sheahan KH., et al. “An overview of GLP-1 agonists and recent cardiovascular outcomes trials”. Postgraduate Medical Journal (2019).
6. Arnott C and Neal B. “Do GLP-1 Receptor Agonists Care if You Have Heart Failure?” Circulation 20 (2019): 1623-1625.
7. Yin WL., et al. “The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes”. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders4 (2020): 835-844.
8. Zinman B., et al. “Liraglutide and Glycaemic Outcomes in the LEADER Trial”. Diabetes Therapy6 (2018): 2383-2392.
9. Steven P Marso., et al. “emaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. The New England Journal of Medicine 375 (2016): 1834-1844.
10. Kaul S. “Key CVOTs with Semaglutide: SUSTAIN 6 and PIONEER 6”. American College of Cardiology (2020).
11. Verma S., et al. “Applying rewind cvd criteria to sustain 6 and pioneer 6: an exploratory analysis of cv outcomes with semaglutide”. Journal of the American College of Cardiology 75 (2020): 1922.
12. Sheahan KH., et al. “An overview of GLP-1 agonists and recent cardiovascular outcomes trials”. Postgraduate Medical Journal 96 (2020): 156-161.
13. Katherine A Lyseng Williamson. “Glucagon Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features”. Clinical Drug Investigation 39 (2019): 805-819.

Citation

Citation: F Nabavizadeh. “GLP-1 Receptor Agonists and Cardiac Outcome Trials in Patients with Type 2 Diabetes". Acta Scientific Cardiovascular System 1.6 (2022): 10-13.

Copyright

Copyright: © 2022 F Nabavizadeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.